U-M to conduct clinical trial to test AstraZeneca COVID-19 vaccine

Author | Kelly Malcom

Michigan Medicine is partnering with the pharmaceutical company AstraZeneca for a Phase 3 clinical trial to test a vaccine against COVID-19. The AZD1222 COVID-19 VACCINE Study will research an investigational vaccine for the prevention of COVID-19, the disease caused by the new coronavirus (SARS-CoV-2).

The study will look at how well the investigational vaccine works and how safe it is. U-M will begin recruiting hundreds of participants for the trial immediately, until the trial is full. U-M is one of several U.S. sites supporting the AstraZeneca trial, with the aim of including 30,000 individuals over a period of two years.

“The importance of a safe and effective vaccine against COVID-19 cannot be overstated. The AstraZeneca Phase III trial will bring answers as to the effectiveness of this vaccine. At the end of the day, this kind of rigorous clinical trial with the commitment of Michigan Medicine and other study sites to safety will be a key step in realizing a vaccine that will save lives when one is developed,” says Marschall Runge, M.D., Ph.D., Dean, U-M Medical School, Executive Vice President, Medical Affairs and CEO, Michigan Medicine.

The AstraZeneca trial is one of several vaccine trials being funded through a public/private partnership under the U.S. Department of Health and Human Services called Operation Warp Speed. It is designed to accelerate the development of a life-saving vaccine to prevent COVID-19, while maintaining standards for safety and efficacy.

“We are proud to advance the University of Michigan's outstanding legacy of excellence in vaccine trials with this important clinical trial partnership. We hope one day soon to be able to announce a successful vaccine against COVID-19 and save lives,” says Mark Schlissel, M.D., Ph.D., president of the University of Michigan.

Phase I/II trials of the vaccine in more than 1000 people were completed earlier this year and demonstrated increased antibody responses against SARS-CoV-2 and no serious adverse effects.

For more information about the study, visit https://www.uofmhealth.org/covid19-vaccine or email [email protected].
Media Contact Public Relations

Department of Communication at Michigan Medicine

[email protected]

734-764-2220

Featured News & Stories cells colorful
Health Lab
Improvements in human genome databases offer a promising future for cancer research
A gene sequencing method called ribosome profiling has expanded our understanding of the human genome by identifying previously unknown protein coding regions. Also known as Ribo-seq, this method allows researchers to get a high-resolution snapshot of protein production in cells.
News Release
Phillip Rodgers, M.D., takes on primary care transformation as new chair of Family Medicine
Puts focus on population-based patient care from birth to end of life, developing core areas of research and training a new generation to lead primary care tomorrow
News Release
Ravi Allada, M.D. to lead Michigan Neuroscience Institute at U-M
A neuroscientist who began his career at the University of Michigan and made important inroads in understanding the mysteries of sleep has returned to Ann Arbor to lead a fast-growing community of scientists studying the brain, nervous system and mind.
 boy sketching comics
Health Lab
Combating Crohn’s with comics
A teenage patient’s unique way of detailing his experience with Crohn’s disease.
 stethoscope in gun outline
Health Lab
Many primary care providers and patients wary of discussing firearms
Screening primary care patients for gun ownership has been recommended especially for people with mental health issues. A Michigan Medicinestudy shows wariness by providers and patients.
 flies moving sled in snow with person
Health Lab
Gene links exercise endurance, cold tolerance and cellular maintenance in flies
A study in PNAS identifies a protein that, when missing, makes exercising in the cold that much harder—that is, at least in fruit flies.